Finally, Section 396 of the FDCA expressly authorizes off-label use: Nothing in this chapter shall be construed to limit or interfere with the authority of a health care practitioner to prescribe or administer any legally marketed device to a patient for any condition or disease within a legitimate health care practitioner-patient relationship. Because physicians lawfully may prescribe off-label, there also is no question that pharmacies lawfully may fill the orders they receive
Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits-The role of the GLP-1 receptor
Patients should never adjust their prescribed dose without consulting their healthcare provider, as semaglutide requires gradual dose escalation to minimize gastrointestinal adverse effects
Some patients increase exercise as part of their weight management program, potentially leading to muscle fatigue and cramping if hydration and electrolyte replacement are inadequate
Patients with kidney disease, liver complications, or type 2 diabetes requiring careful glucose monitoring should consult their healthcare provider before adjusting injection timing
10.1164/rccm.200206-507OC
.jpg)
